LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Raymond James & Associates

Raymond James & Associates reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,844 shares of the medical instruments supplier’s stock after selling 637 shares during the period. Raymond James & Associates owned about 0.13% of LeMaitre Vascular worth $2,373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of LMAT. Van Hulzen Asset Management LLC grew its position in shares of LeMaitre Vascular by 75.1% in the 4th quarter. Van Hulzen Asset Management LLC now owns 23,304 shares of the medical instruments supplier’s stock worth $1,323,000 after acquiring an additional 9,992 shares in the last quarter. Mesirow Institutional Investment Management Inc. bought a new stake in LeMaitre Vascular during the fourth quarter valued at $8,837,000. Johnson Investment Counsel Inc. raised its holdings in shares of LeMaitre Vascular by 26.2% during the fourth quarter. Johnson Investment Counsel Inc. now owns 41,315 shares of the medical instruments supplier’s stock worth $2,345,000 after purchasing an additional 8,570 shares during the period. Jump Financial LLC raised its holdings in shares of LeMaitre Vascular by 25.2% during the fourth quarter. Jump Financial LLC now owns 18,342 shares of the medical instruments supplier’s stock worth $1,041,000 after purchasing an additional 3,692 shares during the period. Finally, Summit Creek Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 37.8% in the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after buying an additional 62,737 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.9 %

Shares of NASDAQ LMAT opened at $90.29 on Tuesday. The stock has a market cap of $2.03 billion, a P/E ratio of 59.79, a P/E/G ratio of 2.38 and a beta of 0.89. The firm’s 50-day simple moving average is $85.22 and its 200 day simple moving average is $75.82. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. During the same period in the prior year, the business posted $0.37 EPS. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research reports. Barrington Research increased their price objective on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. JMP Securities boosted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $90.33.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO George W. Lemaitre sold 12,976 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the completion of the sale, the chief executive officer now directly owns 1,985,358 shares in the company, valued at $170,879,763.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock worth $3,714,994 over the last 90 days. 10.79% of the stock is currently owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.